Bibia Heidmann

This inventor holds 21 USPTO granted patents, plus 10 CIPO patents and 13 EPO patents, primarily in Orexin Receptor Antagonists. Top assignees: Idorsia Pharmaceuticals Ltd, Actelion Pharmaceuticals Ltd. Active years: 2014-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bibia Heidmann. Retrieved from https://idiyas.com/inventor/bibia-heidmann

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 21

% Patents Active = 81.0

CIPO Patents = 10 (Patent Applications = 3)

EPO Patents = 13 (Patent Applications = 14)

Average Co-Inventor Count = 5.2

ph-index = 4

Forward Citations = 64(Granted Patents)

Location History:

Altkirch, FR (2014 - 2016)
Allschwil, CH (2014 - 2023)

Company Filing History:

12 out of 81

Idorsia Pharmaceuticals Ltd

patents

9 out of 217

Actelion Pharmaceuticals Ltd

patents

Years Active: 2014-2023

Loading Chart...

Areas of Expertise:

Orexin Receptor Antagonists

Benzimidazole-Proline Derivatives

Pyrazole Compounds

Triazole Compounds

Azetidine Amide Derivatives

Proline Sulfonamide Derivatives

Lactam Derivatives

Calcium Channel Blockers

Crystalline Forms

Pharmaceutical Compounds

Antimalarial Agents

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11555025 - Crystalline form of N-[1-(5-cyano-pyridin-2-ylmethyl)-1 H-pyrazol-3-yl]-2- [4-(1-trifluoromethyl-cyclopropyl)-phenyl-acetamide (2023-01-17),

2. 11059803 - Crystalline form of N-[1-(5-cyano-pyridin-2- ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide (2021-07-13),

3. 11040966 - Benzimidazole-proline derivatives (2021-06-22),

4. 10329287 - Benzimidazole-proline derivatives (2019-06-25),

5. 10246426 - Triazole compounds as T-type calcium channel blockers (2019-04-02),

6. 10065929 - Pyrazole compounds and their use as T-type calcium channel blockers (2018-09-04),

7. 10023560 - Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist (2018-07-17),

8. 9932314 - Pyrazole compounds and their use as T-type calcium channel blockers (2018-04-03),

9. 9914721 - Use of benzimidazole-proline derivatives (2018-03-13),

10. 9914720 - Crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[D]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists (2018-03-13),

11. 9790208 - Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist (2017-10-17),

12. 9732075 - Benzimidazole-proline derivatives (2017-08-15),

13. 9493446 - [object Object] (2016-11-15),

14. 9403813 - Azetidine amide derivatives as orexin receptor antagonists (2016-08-02),

15. 9303023 - Pyrazole and imidazole derivatives useful as orexin antagonists (2016-04-05),

Title: Bibia Heidmann: Innovator in Pharmaceutical Sciences

Introduction

Bibia Heidmann is a prominent inventor based in Allschwil, Switzerland, known for his significant contributions to pharmaceutical innovations. With a remarkable portfolio of 21 patents, Heidmann has carved a niche in the development of novel pharmaceutical compounds, particularly in the area of T-type calcium channel blockers.

Latest Patents

Among his latest innovations, Heidmann has patented crystalline forms of N-[1-(5-cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide. This invention relates to pharmaceutical compositions that utilize these crystalline forms, which demonstrate potential uses in the treatment or prevention of diseases where T-type calcium channels play a critical role. His work not only advances medicinal chemistry but also paves the way for new therapeutic options.

Career Highlights

Heidmann has had a distinguished career working with industry leaders such as Idorsia Pharmaceuticals Ltd and Actelion Pharmaceuticals Ltd. His experience in these companies has been instrumental in shaping his expertise and innovation strategies within the pharmaceutical sector.

Collaborations

Throughout his career, Heidmann has collaborated with talented individuals like Christoph Boss and Christine Brotschi. These collaborations have allowed him to leverage diverse perspectives and expertise, enhancing the quality and impact of his inventions.

Conclusion

Bibia Heidmann's contributions to the field of pharmaceuticals stand as a testament to his creativity and dedication as an inventor. His innovative spirit and collaborative efforts continue to inspire advancements that may lead to significant breakthroughs in medical treatments. With an impressive number of patents and ongoing research, Heidmann is poised to remain a key figure in pharmaceutical innovation.

Profile summary based on public USPTO records.